University of Pennsylvania and Syracuse University scientists have discovered that a hindbrain-derived peptide, octadecaneuropeptide (ODN), can suppress appetite and improve glucose regulation without causing nausea or vomiting. Results suggest a glia-to-neuron signaling axis in the dorsal vagal complex that may be harnessed for treating obesity and type 2 diabetes.

Glial cells in the brainstem produce ODN, a signaling peptide whose physiological role in energy homeostasis has remained obscure. Researchers now find that directly activating this peptide system in the hindbrain induces weight loss, enhances glucose disposal, and lowers insulin resistance in obese animals.

Unlike existing therapies targeting GLP-1 receptors, ODN achieves these effects without triggering nausea-related behaviors or emesis in vomiting-competent models.